Concepedia

Stephanos Ioannidis

SI

Statistics

Publications

24

Citations

2K

H-Index

19

Active since

2005

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (United Kingdom)

Forma Therapeutics (United States)

University of Oxford

University of Liverpool

Stephanos Ioannidis is an author at AstraZeneca (United States) specializing in drug discovery, pharmacology, and medicinal chemistry.

Publications per year

2005–2020

24

Publications

24

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

Michael Hedvat, Dennis Huszar, Andreas Herrmann et al. · Cancer Cell · 2009 · 529 citations · Full text

, , +9

Molecular basis of USP7 inhibition by selective small-molecule inhibitors

A.P. Turnbull, Stephanos Ioannidis, Wojciech Krajewski et al. · Nature · 2017 · 468 citations

, , +14

USP30 sets a trigger threshold for PINK1–PARKIN amplification of mitochondrial ubiquitylation

Emma V. Rusilowicz-Jones, Jane Jardine, Andreas Kallinos et al. · Life Science Alliance · 2020 · 130 citations · Full text

, , +17

Discovery of 5-Chloro-<i>N</i><sup>2</sup>-[(1<i>S</i>)-1-(5-fluoropyrimidin-2-yl)ethyl]-<i>N</i><sup>4</sup>-(5-methyl-1<i>H</i>-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway

Stephanos Ioannidis, Michelle L. Lamb, Tao Wang et al. · Journal of Medicinal Chemistry · 2010 · 123 citations · Full text

, , +15

Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2

Joseph M. Gozgit, Geraldine Bebernitz, Pankaj Patil et al. · Journal of Biological Chemistry · 2008 · 101 citations · Full text

, , +13

1–5 of 24